Evidence based guidelines for treatment of primary headaghes

Acta Clinica Croatica

Volumn 44, Issue 2, 2005, Pages 139-183

  Demarin, Vida ^a   Vuković, Vlasta ^a   Lovrenčić Huzjan, Arijana ^a   Lušić, Ivo ^b   Jančuljak, Davor ^c   Wilheim, Ksenija ^d   Zurak, Niko ^e  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^d KBC RIJEKA   (Croatia)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cluster headache; Headache management; Migraine; Pharmacotherapy; Tension headache

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTIEMETIC AGENT; ATENOLOL; BUTALBITAL; CAFFEINE; CHLORPROMAZINE; DEXAMETHASONE; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; HYDROCORTISONE; ISOMETHEPTENE; LIDOCAINE; METOCLOPRAMIDE; METOPROLOL; NADOLOL; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROCHLORPERAZINE; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TIMOLOL; UNINDEXED DRUG; ZOLMITRIPTAN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AKATHISIA; ALOPECIA; ANAPHYLAXIS; ANGIOGRAPHY; ASTHENIA; ASTHMA; BEHAVIOR THERAPY; BLOOD DISEASE; BRADYCARDIA; CLAUDICATION; CLINICAL TRIAL; CLUSTER HEADACHE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DYSTONIA; ELECTROENCEPHALOGRAPHY; EMERGENCY WARD; ERGOTISM; ERYTHEMA; EVIDENCE BASED MEDICINE; FAMILIAL HEMIPLEGIC MIGRAINE; FATIGUE; FIBROSIS; FLUSHING; GANGRENE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART MUSCLE ISCHEMIA; HEAT; HEPATITIS; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPERTENSION; IMPOTENCE; INCREASED APPETITE; INJECTION SITE REACTION; LABORATORY TEST; LETHARGY; LIVER DYSFUNCTION; LUMBAR PUNCTURE; MAXIMUM PERMISSIBLE DOSE; MEMORY DISORDER; MENOPAUSE; MENTAL DISEASE; META ANALYSIS; MIGRAINE; MIGRAINE AURA; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROIMAGING; NEUROPATHY; NIGHTMARE; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PHYSIOTHERAPY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; RASH; REVIEW; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TASTE DISORDER; TENSION HEADACHE; TOXIC EPIDERMAL NECROLYSIS; URINE RETENTION; URTICARIA; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 23044478873     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (235)

1. GOADSBY P, OLESEN J. Diagnosis and management of migraine. BMJ 1996;312:1279-83.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24 (Suppl 1):14-15.
3. American College of Emergency Physicians (ACEP). Clinical policy: critical isssues in the evaluation and management of patients presenting to the emergency department with acute headache. Ann Emerg Med 2002;39:108-22.
4. SILBERSTEIN SD, SAPER JR, FREITAG EG. Migraine: diagnosis and treatment. In: SILBERSTEIN SD, LIPTON RB, DALESSIO DJ, eds. Wolf's headache and other head pain, 7th edition. Oxford: Oxford University Press, 2001:121-237.
5. ERISHBERG BM, ROSENBERG JH, MATCHAR DB, McCRORY DC, PIETRZAK MP, ROZEN TD, SILBERSTEIN SD. Evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. Available at http://www.aan.com. Accessed May 2003.
6. EDMEADS J, MACKELL JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002;42:501-9.
7. RASMUSSEN BK, JENSEN R, SCHROLL M et al. Epidemiology of headache in general population: a prevalence study. J Clin Epidemiol 1991;44:1147-57.
8. STEWART WF, LIPTON RB, CELENTANO DD et al. Prevalence of migraine headache in the United States. JAMA 1992;267:64-9.
9. O'BRIEN B, GOEREE R, STEINER D. Prevalence of migraine headache in Canada: a population-based survey. J Epidemiol 1994;23:1020-6.
10. HENRY P, MICHEL P, BROCHET B et al. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992;12:229-37.
11. STEWART WF, LIPTON RB, LIBERMAN J. Variations in migraine prevalence by race. Neurology 1996;47:52-9.
12. MOSKOWITZ MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43 (Suppl 3):16-20.
13. DEMARIN V, RUNDEK T, PODOBNIK-ŠARKANJI S, LOVRENČIĆ- HUZJAN A. A correlation of 5-hydroxytryptamine and cerebral vasoreactivity in patients with migraine. Funct Neurol 1994;9:235-45.
14. LOVRENČIĆ-HUZJAN A, DEMARIN V, RUNDEK T, ŠERIĆ V. Cerebral haemodynamic changes during migraine attack. Period Biol 1995;97:127-32.
15. LOVRENČIĆ-HUZJAN A, DEMARIN V, RUNDEK T, VUKOVIĆ V. Role of vertebral artery hypoplasia in migraine. Cephalalgia 1998;18:684-6.
16. LOVRENČIĆ-HUZJAN A, DEMARIN V, MALIĆ M. Sumatriptan ne uzrokuje značajnu moždanu vazokonstrikciju u migreni. Neurol Croat 1999;48:119-26.
17. LOVRENČIĆ-HUZJAN A, DEMARIN V. Cerebral hemodynamic changes in migraine patients overusing ergotamine: four case reports. Acta Clin Croat 1999;38:245-50.
18. PEROUTKA SJ. Genetic basis of migraine. Clin Neurosci 1998;5:34-7.
19. DUCROS A, TOURNIER-LASSERVE E, BOUSSER MG. The genetics of migraine. Lancet Neurol 2002;5:285-93.
20. American Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994;44:1353-4.
21. EVANS R, ROZEN TD, ADELMAN JU. Neuroimaging and other diagnostic testing in headache. In: SILBERSTEIN SD, LIPTON RB, DALESSIO DJ, eds. Wolf's headache and other head pain, 7th edition. Oxford: Oxford University Press, 2001:27-49.
22. ŽIVADINOV R, WILHEIM K, SEPIĆ-GRAHOVAC D, JURJEVIĆ A, BUČUK M, BRNABIĆ-RAZMILIĆ O, RELJA G, ZORZON M. Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia 2003;23:336-43.
23. BLAU JN. Adult migraine: the patient observed. In: BLAU JN, ed. Migraine: clinical, therapeutic, conceptual and research aspects. London: Chapman and Hall, 1987:3-30.
24. PEATFIELD RC. Relationships between food, wine, and beer precipitated migrainous headaches. Headache 1995;35:355-7.
25. FORWARD SP, McGRATH PJ, MacKINNON D et al. Medication patterns of recurrent headache sufferers: a community study. Cephalalgia 1998;18:146-51.
26. MATCHAR DB, YOUNG WB, ROSENBERG JH, PIETRZAK MP, SILBERSTEIN SD, LIPTON RB, RADMANN NM. Evidence-based guidelines in the primary care setting: pharmacological management of acute attacks. Available at:http:// www.aan.com. Accessed May 2003.
27. SILBERSTEIN SD. Practice parameter-evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 2000;55:754-62.
28. SNOW V, WEISS K, WALL E, MOTTUR-PILSON C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;137:840-52.
29. LOVRENČIĆ-HUZJAN A, HERCEG M, BILUŠIĆ M, IVANČAN V. Lijekovi s učinkom na živčani sustav. In: Vrhovac B, ed. Farmakoterapijski prirucnik, 4th edition. Zagreb: Medicinska naklada, 2003:437-526.
30. TFELT-HANSEN P, HENRY P, MULDER LJ et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6.
31. SILBERSTEIN SD, McCRORY DC. Butalbital in the treatment of headache: history, pharmacology and efficacy. Headache 2001;41:953-67.
32. SILBERSTEIN SD, McCRORY DS. Opioids. Cephalalgia 2000;20:854-64.
33. KLAPPER J, STANTON J. The emergency treatment of acute migraine headache: a comparison of intraveneous dihydroergotamine, dexamethasone and placebo. Cephalalgia 1991;11 (Suppl 11):159-60.
34. MAIZELS M, SCOTT B, COHEN W, CHEN W. Intranasal lidocaine for treatment of migraine: a randomized, double blind, controlled trial. JAMA 1996;276:319-21.
35. JONES J, SKLAR D, DOUGHERTY J, WHITE W. Randomized double-blind trial of intraveneous prochlorperazine for the treatment of acute headache. JAMA 1989;fali volumen:261-76.
36. CARPAY JA, LINSSEN HJP, KOEHLER JJ, ARENDS LR, TIEDINK HGM. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. Headache 2003;43:395-9.
37. FERRARI MD. The subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21.
38. TFELT-HANSEN P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18:532-8.
39. TFELT-HANSEN P. A comparative review of pharmacology, pharmacokinetics and efficacy of triptans in migraine. Drugs 2000;6:1259-87.
40. PALMER KJ, SPENCER CM. Zolmitriptan. CNS Drugs 1997;7:468-78.
41. KLASSEN A, ELKIND A, ASGHARNEJAD M, WEBSTER C, LAURENZA A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel group study. Headache 1997;37:640-5.
42. BLOCK GA, GOLDSTEIN J, POLIS A, REINES SA, SMITH ME. The Rizatriptan Multicenter Study Group. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998;38:764-71.
43. KRAMER MS, MATZURA-WOLFE D, POLIS A, GETSON A, AMARENI PG, SOLBACH MP et al. A placebo-controlled cross-over study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998;51:773-81.
44. MATHEW NT. Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache 2002;42:32-40.
45. PFAFFENRATH V, CUNIN G, SJONELL G, PRENDERGAST S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine; defining the optimum doses for oral sumatriptan. Headache 1998;38:184-90.
46. DAHLOF C, FABRI M, LOFTUS J, JONES M, MANSBACH H, SCOTT A. Triptan efficacy and preference: results of a randomized, multi-centre, open-label, crossover study of sumatriptan, naratriptan, rizatriptan and zolmitriptan tablets in acute treatment of migraine. Cephalalgia 2001;21:410.
47. DOWSON AJ, BOES-HANSEN S, FARKKILA AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000;7 (Suppl 3):82.
48. CABARROCAS X, SALVA M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997;17:421.
49. BUCHAN P, WARD C, ZEIG S. Frovatripan pharmacokinetics is unaffected during a migraine attack. Cephalalgia 1999;19:365.
50. NAPPI G, SICUTERI F, BYRNE M, RONCOLATO M, ZERBINI O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138-44.
51. SARGENT J, KIRCHNER JR, DAVIS R, KIRKHART B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995;45 (Suppl 7):10-4.
52. REDERICH G, RAPOPORT A, CUTLER N, HAZELRIGG R, JAMERSON B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995;45 (Suppl 7):15-20.
53. DAHLOF C, DIENER HC, GOADSBYP J, MASSIOU H, OLESEN J, SCHOENEN J et al. Zolmitriptan, a 5-HT 1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998;5:535-43.
54. STEINER TJ. Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: results of a phase III study. Cephalalgia 1998;18:385.
55. GOADSBY PJ, FERRARI MD, OLESEN J, STOVNER LJ, SENARD JM, JACKSON NC et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54:156-63.
56. ROBERT M, CABARROCAS X, FERNANDEZ FJ, ZAYAS JM, FERRER P. Almotriptan Multiple Attack Study Group. Efficacy and tolerability of oral almotriptan in the treatment of migraine. Cephalalgia 1998;18:406.
57. McDAVIS HL, HUTCHINSON J. Frovatriptan phase III Investigators. Frovatriptan - new overall clinical efficacy. Cephalalgia 1999;19:363-4.
58. MAUSKOP A, FARKKILA M, HERING-HANIT R, RAPOPORT A, WARNER J. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Curr Med Res Opin 1999;15:282-9.
59. TEPPER SJ, RAPOPORT AM. The triptans: a summary. CNS Drugs 1999;12:403-17.
60. FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
61. LIPTON RB, CADY RK, O'QUINN S, HALL CB, STEWART WF. Sumatriptan treats the full spectrum of headache in individuals with disabling HIS migraine. Headache 1999;40:783-91.
62. HALL GC, BROWN MM, MacRAE KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-8.
63. GOLDSTEIN JA, MASSEY KD, KIRBY S, GIBSON M et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004;24:515-21.
64. FERRARI MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999;19 (Suppl 23):2-8.
65. SILBERSTEIN SD. Migraine. Lancet 2004;363:381-91.
66. GERAUD, G, KEYWOOD C, SENARSD JM. Migraine headache recurrence to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003;43:376-88.
67. LOFLAND JH, KIM SS, BATENHORST AS, JOHNSON NE et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001;76:1093-101.
68. TFELT-HANSEN P, SAXENA PR, DAHLOF C, PASCUAL J, LAINEZ M, HENRY P et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000;123:9-18.
69. MATHEW NT. Dosing and administration of ergotamine tartarate and dihydroergotamine. Headache 1997;37 (Suppl 1):26-32.
70. TOUCHON J, BERTIN L, PILGRIM AJ, ASHFORD E, BES A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361-5.
71. EVERS S, GRALOW I, BAUER B, SUHR B, BUCHHEISTER A et al. Sumatriptan and ergotamine overuse and drug induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999;22:201-6.
72. LIPTON RB. Ergotamine tartarate and dihydroergotamine mesylate: safety profiles. Headache 1997;37 (Suppl 1):33-41.
73. Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines for Migraine and Cluster Headache. Prophylactic treatment of migraine. J Headache Pain 2001;2:147-61.
74. SILBERSTEIN SD, GOADSBY PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
75. RAMADAN NM, SILBERSTEIN SD, FREITAG FG, GILBERT TT, FRISHBERG BM. Evidence-Based Guidelines in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. Available at: http://www.aan.com. Accessed May 2003.
76. DIENER HC, KAUBE H, LIMMROTH V. A practical guide to the management and prevention of migraine. Drugs 1998;56:811-24.
77. LIMMROTH V, MICHEL MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoreceptor blockers. Br J Clin Pharmacol 2001;52:237-43.
78. ANDERSON K, VINGE E. Beta-adrenoreceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-73.
79. HOLROYD KA, PENZIEN DB, COORDINGLEY GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31:333-40.
80. OLESEN J, TFELT-HANSEN P, WELCH KMA, eds. The headaches. New York: Raven Press, 1993.
81. KANGASNIEMI P, ANDERSEN AR, ANDERSEN PG et al. Classic migraine - effective prophylaxis with metoprolol. Cephalalgia 1987;7:231-8.
82. FRISHMAN WH. Beta adrenergic blocker withdrawal. Am J Cardiol 1987;59:32F.
83. COUCH JR, HASSANEIN RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9.
84. COUCH JR, HASSANEIN RS. Migraine and depression: effect of amitriptyline prophylaxis. Trans Am Neurol Assoc 1976;101:234-7.
85. MATHEW NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache 1981;21:105-9.
86. BANK J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994;34:476-8.
87. OGUZHANOGLU A, SAHINER T, KURT T, AKALIN O. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension type headache. Cephalalgia 1999;19:531-2.
88. DIENER HC, FÖH M, IACCARINO C et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996;16:441-7.
89. DIAMOND S, FREITAG FG. A double blind trial of flunarizine in migraine prophylaxis. Headache 1993;4:169-72.
90. LOUIS P. A double-blind placebo controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981;21:235-9.
91. MENDENOPOULOS G, MANAFI T, LOGOTHETIS I, BOSTANTJOPOILOU S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985;5:31-7.
92. GAWEL MJ, KREEFT J, NELSON RF et al. Comparison of the efficacy and safety of funarizine or propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992;19:340-5.
93. SORENSEN PS, LARESN BH, RASMUSSEN MJ et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;10:657.
94. CLELAND PG, BARNES D, ELRINGTON GM et al. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997:38:31-8.
95. SILBERSTEIN SD. Methysergide. Cephalalgia 1998;18:421-35.
96. PEATIFIELD R. Drugs acting by modification of serotonin function. Headache 1986;26:129-31.
97. RASCOL A, MONTASTRUC JL, RASCOL O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986;26:83-5.
98. FORSSMAN B, HENRIKSSON KG, KIHLSTRAND S. A comparison between BC105 and methysergide in the prophylaxis of migraine. Acta Neurol Scand 1972;48:204-12.
99. VILMING S, STANDNES B, HEDMAN C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 1985;5:17-23.
100. BEHAN PO, REID M. Propranolol in the treatment of migraine. Practitioner 1980;224:201-4.
101. HERING R, KURITZKY A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus palcebo. Cepahalalgia 1992;12:81-4.
102. KLAPPER JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Q 1995;5:50-3.
103. KLAPPER JA. Divalproex sodium in migraine prophylaxis: a dose controlled study. Cephalalgia 1997;17:103-8.
104. JENSEN R, BRINCK T, OLESEN J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994;44:647-51.
105. KANIECKI RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:1141-5.
106. SILBERSTEIN SD, COLLINS SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group). Headache 1999;39:633-43.
107. MATHEW NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996;16:367.
108. MATHEW NT, RAPOPORT A, SAPER J, MAGNUS L, KLAPPER J, RAMADAN N et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28.
109. WESSELY P, BAUMGARTNER C, KLINGER D, KRECZI J, MEYERSON N, SAILER L et al. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin. Cephalalgia 1987;7:477-8.
110. POTTER DL, HART DE, CALDER CS, STOREY JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migriane. Neurology 2000;54:A15. (abstract)
111. EDWARDS KR, GLANTZ MJ, SHEA P, NORTON JA, CROSS N. A double blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. Cephalalgia 2000;20:316. (abstract)
112. STEINER TJ, FINDLEY LJ, YUEN AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-12.
113. D'ANDREA G, GRANELLA F, CADALDINI M, MANZONI GC. Effectivenesss of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999;19:64-6.
114. LAMPL C, BUZATH A, KLINGER D, NEUMANN K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia 1999;19:58-63.
115. O'NEAL BP, MANN JD. Aspirin prophylaxis in migraine. Lancet 1978;2:1179-81.
116. MASEL BE, CHESSON AL, PETERS BH, LEVIN HS, ALPERIN JB. Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. Headache 1980;20:13-8.
117. SALOMON GD, KUNKEL RS. Flurbiprofen in the prophylaxis of migraine. Cleve Clin J Med 1993;60:43-8.
118. STENSRUD P, SJAASTAD O. Clinical trial of a new antibradykinin, anti-inflammatory drug, ketoprofen, in migraine prophylaxis. Headache 1974;14:96-100.
119. SANCES G, MARTIGNONI E, FIORONI L, BLANDINI F, FACCHINETII F, NAPPI G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990;30:705-9.
120. SZEKEL B, MERRYMAN S, CROFT H, POST G. Prophylactic effect of naproxen sodium on perimenstrual headache: a double blind placebo controlled study. Cephalalgia 1989;9 (Suppl 10):452-3.
121. SCHOENEN J, JACQUY J, LENAERTS M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-70.
122. VOLGER BK, PITTLER MH, ERNST E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8.
123. PFAFFENRATH V, DIENER HC, FISCHER M, FRIEDE M, HENNEICKE-von ZEPELIN HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double blind, multicentre, randomized, placebo-controlled, dose-response study. Cephalalgia 2002;22:523-32.
124. BOSKA MD, WELCH KMA, BARKER PB, NELSON JA, SCHULTZ L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002;58:1227-33.
125. PEIKERT A, WILIMZIG C, KÖHNE-VOLLAND R. Prophylaxis of migraine with oral magnesium: results from a prospective multi-center, placebo-controlled and double blind randomized study. Cephalalgia 1996;16:257-63.
126. MAUSKOP A, ALTURA BT, CRACCO RQ, ALTURA BM. Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels. Neurology 1995;45:A379. (abstract)
127. MONTAGNA P, CORTFELLI P, BARBIROLI B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia 1994;14:184-93.
128. BRESOLIN N, MARTINELLI P, BARBIROLI B et al. Muscle mitochondrial deletion and 31P NMR spectroscopy alterations in migraine patients. J Neruol Sci 1991;104:182-9.
129. BARBIROLI B, MONTAGNA P, MARTINELLI P et al. Improved brain and muscle energy metabolism in patients with mitochondrial cytopathies treated with coenzyme Q10. Neurology 1994;2 (Suppl):404.
130. ROZEN TD, OSHINSKY ML, GEBELINE CA, BRADLEY KC, YOUNG WB, SHECHTER AL, SILBERSTEIN SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41.
131. SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-50.
132. BRIN MF, SWOPE DM, O'BRIAN C, ABBASI S, POGODA JM. Botox for migraine: double-blind, placebo-controlled, region specific evaluation. Cephalalgia 2000;20:421-2.
133. BINDER WJ, BRIN MF, BLITZER A, SCHOENROCK LD, POGODA JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-76.
134. MAUSKOP A, BASDEO R. Botulinum toxin is an effective prophylactic therapy for migraines. Cephalalgia 2000;20:422.
135. EVERS S, RAHMANN J, VOLLMER-HAASE J, HUSSTEDT IW. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 2002;22:699-710.
136. GOBEL H. Botulinum toxin in migraine prophylaxis. J Neurol 2004;251 (Suppl 1):8-11.
137. EFTEDAL OS, LYDERSEN S, HELDE G, WHITE L, BRUBAKK AO, STOVNER LJ. A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine. Cephalalgia 2004;24:639-44.
138. MYERS DE, MYERS RA. A preliminary report on hyperbaric oxygen in the relief of migraine headache. Headache 1995;35:197-9.
139. WILSON JR, FORESMAN BH, GABER RG, WRIGHT T. Hyperbaric oxygen in the treatment of migraine with aura. Headache 1998;38:112-5.
140. SOYKA D, FRIELING B. Lisuride for the prevention of migraine. Results of a multicenter study. Fortschr Med 1989;107:763-6.
141. RAPOPORT AM, BIGAL ME, VOLCY M, SHEPTELL FD, FELEPPA M, TEPPER SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache 2003;43:482-9.
142. SILBERSTEIN SD, PERES MF, HOPKINS MM, SHECHTER AL, YOUNG WB, ROZEN TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002;42:515-8.
143. LIPTON RB, SILBERSTEIN SD, SAPER JR, BIGAL ME, GOADSBY PJ. Why headache treatment fails. Neurology 2003;60:1064-70.
144. Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines for Migraine and Cluster Headache. Prophylactic treatment of migraine. J Headache Pain 2001;2:162-7.
145. DALY EJ, DONN PA, GALLIHER MJ, ZIMMERMAN JS. Biofeedback applications to migraine and tension headaches: a double-blinded outcome stuudy. Biofeedback Self Regul 1983;8:135-52.
146. BROWN JM. Imagery coping strategies in the treatment of migraine. Pain 1984;18:157-67.
147. SORBI M, TELLEGEN B. Differential effects of training in relaxation and stress-coping in patients with migraine. Headache 1986;26:473-81.
148. SARGENT J, SOLBACH P, COYBE L, PSOHN H, SEGERSON J. Results of a controlled, experimental, outcome study of non drug treatment for the control of migraine headaches. J Behav Med 1986;9:291-323.
149. BILD R, ADAMS HE. Modification of migraine headaches by cephalic blood volume pulse and EMG biofeedback. J Consult Clin Psychol 1980;48:51-7.
150. GAUTHIER J, LACROIX R, COTE A, DOYON J, DROLET M. Biofeedback control of migraine headaches: a comparison of two approaches. Biofeedback Self Regul 1985;10:139-59.
151. BLANCHARD EB, APPELBAUM KA, RADNITZ CL, MORRILL B, MICHULTKA D, KIRSCH C et al. A controlled evaluation of thermal biofeedback combined with cognitive therapy in the treatment of vascular headache. J Consult Clin Psychol 1990;58:216-24.
152. BLANCHARD EB, APPELBAUM KA, NICHOLSON NL, RADNITZ CL et al. A controlled evaluation of the addition of cognitive therapy to a home-based biofeedback and relaxation treatment of vascular headache. Headache 1990;30:371-6.
153. MARCUS DA, SCHARFF L, MERCER S, TURK DC. Nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback. Cephalalgia 1998;18:266-72.
154. HOLROYD KA, FRANCE JL, CORDINGLEY GE, ROKICKI LA et al. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. J Consult Clin Psychol 1995;63:327-30.
155. KISCH I. Hypnosis as an adjunct to cognitive-behavioral psychotherapy: a meta-analysis. J Consult Clin Psychol 1995;63:214-20.
156. Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines for Migraine and Cluster Headache. Non-pharmacological therapy of migraine. J Headache Pain 2001;2:162-7.
157. PARKER GB, TUPLING H, PRYOR DS. A controlled trial of cervical manipulation of migraine. Aust N Z J 1978;8:589-93.
158. NELSON CF, BRONFORT G, EVANS R, BOLINE P, GOLD-SMITH C, ANDERSON R. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. J Manipulative Physiol Ther 1998;21:511-9.
159. MacGREGOR EA. "Menstrual" migraine: towards a definition. Cephalalgia 1996;16:11-21.
160. BOUSSER MG, CONRAD J, KITTNER S, De LIGNIERES B, MacGREGOR EA, MASSIOU H, SILBERSTEIN SD, TZOURIO C. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and homone replacement therapy in women with migraine. Cephalalgia 2000;20:155-6.
161. MASSIOU H, MacGREGOR EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170-4.
162. DENNERSTEIN L, MORSE C, BURROWS G, OATS J et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988;2:113-20.
163. PFAFFENRATH V. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia 1993;13 (Suppl 13):244.
164. Institute for Clinical Systems Improvement (ICSI). Migraine headache. Available at: http://www.neurology.org. Accessed May 2003.
165. BECKER J. Use of oral contraceptives in patients with migraine. Neurology 1999;53 (Suppl 1):19-25.
166. SILBERSTEIN SD, DeLIGNIERES B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000;20:214-21.
167. SILBERSTEIN SD. Headache and female hormones: what you need to know. Neurology 2001;14:323-33.
168. ETMINAM M, TAKKOUCHE B, CAAMANO I, SAMII A. Risk of ischemic stroke in people with migraine: systematic review and meta-analysis of observational studies. Available at: http://www.bmj.com. Accessed December 2004.
169. MILHAUD D, BOGOUSSLAVSKY J, van MELLE G, LIOT P. Ischemic stroke and active migraine. Neurology 2001;27:1805-11.
170. VUKOVIĆ y LOVRENČIĆ-HUZJAN A, VARGEK-SOLTER V, crossed D signORcrossed D signEVIĆ V, DEMARIN V. Hormone replacement therapy - is there a place for its use in neurology? Coll Antropol 2003;27:413-24.
171. SANGES G, GRANELLA F, NAPPI RE, FIGNON A, GHIOTTO N, POLATTI F, NAPPI G. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003;23:197-205.
172. RASMUSSEN BK, JENSEN R, OLESEN J. A population-based analysis of the diagnostic criteria of The International Headache Society. Cephalalgia 1991;11:129-34.
173. GOADSBY PJ, BOES C. Chronic daily headache. J Neurol Neurosurg Psychiatry 2002;72 (Suppl 2):2-5.
174. ASHINA M, BENDTSEN L, JENSEN R, SAKAI F, OLESEN J. Muscle hardness in patients with chronic tension-type headache: relation to actual headache state. Pain 1999;79:201-5.
175. JENSEN R, BENDSEN L, OLESEN J. Muscular factors are of importance in tension-type headache. Headache 1998;38:10-7.
176. BENDSEN L. Central sensitization in tension-type headache - possible pathophysiological mechanisms. Cephalalgia 2000;20:486-508.
177. JENSEN R, OLESEN J. Tension-type headache: an update on mechanisms and treatment. Curr Opin Neurol 2000;13:285-9.
178. HOLROYD KA, O'DONELL FJ, STENSLAND M, LIPCHIK GL et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination. A randomized controlled trial. J Am Med Assoc 2001;285:2208-15.
179. CERBO R, BARBANTI P, FABBRINI G et al. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenic implications. Headache 1998;38:453-7.
180. BUSSONE G, SANDRINI G, PATRUNO G et al. Effectiveness of fluoxetine on pain and depression in chronic headache disorders. In: NAPPI G, BOBO G, SANDRINI G, eds. Headache and depression: serotonin pathways as a common clue. New York: Raven Press, 1991:265-72.
181. ONDO WG, VUONG KD, DERMAN HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5.
182. RELJA M, TELAROVIĆ S. Botulinum toxin in tension-type headache. J Neurol 2004;251 (Suppl 1):12-4.
183. SCHULTE-MATTLER WJ, WIESER T, ZIERZ S. Treatment of tension-type headache with botulinum toxin. A pilot study. Eur J Med Res 1999;4:183-6.
184. RELJA M. Treatment of tension-type headache with botulinum toxin: 1 year-follow-up. Cephalalgia 2000;20:236.
185. PADBERG M, De BRUIJN SFTM, De HAAN RJ, TAW DLj. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675-80.
186. MANZONI GC, MICIELI G, GRANELLA F, TASSORELLI C, ZANFERRARI C, CAVALLINI A. A cluster headache - course over ten years in 189 patients. Cephalalgia 1991;11:169-74.
187. EKBOM K. Pattern of cluster headache with a note on the relation to angina pectoris and peptic ulcer. Acta Neurol Scand 1970;46:225-37.
188. MANZONI GC. Epidemiological and clinical aspects of cluster headache: relation with the migrainous syndrome. Ital J Neurol Sci 1999;20:6-7.
189. MANZONI GC, TERZANO MG, BONO G, MICIELI G, MARTUCCI N, NAPPI G. Cluster headache-clinical findings in 180 patients. Cephalalgia 1983;3:21-30.
190. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 1962;179:717-8.
191. HAIMANOT RT, SERAW B, FORSGREN L, EKBOM K, EKSTEDT J. Migraine, chronic tension-type headache and cluster headache in an Ethiopian rural community. Cephalalgia 1995;15:482-8.
192. RUSSELL MB, ANDERSSON PG, THOMSEN LL. Familial occurrence of cluster headache. J Neurol Neurosurg Psychiatry 1995;58:341-3.
193. Italian Cooperative Study Group on the Epidemiology of Cluster Headache (ICECH). Case-control study on the epidemiology of cluster headache I: Etiological factors and associated conditions. Neuroepidemiology 1995;14:123-7.
194. Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines for Migraine and Cluster Headache. Diagnosis, symptomatic therapy and preventive therapy of cluster headache. J Headache Pain 2001;2:168-79.
195. DEMARIN V et al. Priručnik iz neurologije. Zagreb: Prosvjeta, 1998.
196. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322-6.
197. EKBOM K, MONSTAD I, PRUSINSKI A, COLE JA, PILGRIM AJ, NORONHA D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993;88:63-9.
198. EKBOM K, KRABBE E, MICIELI G, PRUSINSKI A, COLE JA, PILGRIM AJ, NORONHA D. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-Term Study Group. Cephalalgia 1995;15:230-6.
199. GÖBEL H, LINDNER V, HEINZE A, RIBBAT M, DEUSCHL G. Acute therapy for cluster headache with sumatriptan: findings of one-year long-term study. Neurology 1998;51:908-11.
200. HARDEBO JE. Subcutaneous sumatriptan in cluster headache: a time study of the effect on pain and autonomic symptoms. Headache 1993;33:18-21.
201. HARDEBO JE, DAHLÖF C. Sumatriptan nasal spray (20 mg/ dose) in the acute treatment of cluster headache 1998;18:487-9.
202. BAHRA A, GAWEL MJ, HARDEBO JE, MILLSON D, BREEN SA, GOADSBY PJ. Oral zolmitriptan is effective in the acute treatment of cluster headache 2000;54:1832-9.
203. FOGAN L. Treatment of cluster headache. A double blind comparison of oxygen vs. air inhalation. Arch Neurol 1985;42:362-3.
204. KUDROW L. Response of cluster headache attacks to oxygen inhalation. Headache 1981;21:1-4.
205. Di SABATO F, FUSCO BM, PELAIA P, GIACOVAZZO M. Hyperbaric oxygen therapy in cluster headache. Pain 1993;52:243-5.
206. PORTA M, GRANELLA F, COPPOLA A, LONGONI C, MANZONI GC. Treatment of cluster headache attacks with hyperbaric oxygen. Cephalalgia 1991;11 (Suppl 11):236-7.
207. HORTON BT, RYAN R, REYNOLDS JL. Clinical observations on the use of E.C. 110, a new agent for the treatment of headache. Proc Mayo Clin 1948;23:105-8.
208. MAGEE KR, WESTERBERG MR, DeJONG RM. Treatment of headache with ergotamine caffeine suppositories. Neurology 1952;2:477-80.
209. ANDERSON PG, JESPERSEN LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986;6:51-4.
210. ROBBINS L. Intranasal lidocaine for cluster headache. Headache 1995;35:83-4.
211. GABAI IJ, SPIERINGS EL. Prophylactic treatment of cluster headache with verapamil. Headache 1989;29:167-8.
212. LEONE M, D'AMICO D, FERDIANI F, MOSCHIANO F, GRAZZI L, ATTANASIO A, BUSSONE G. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 2000;54:1382-5.
213. PRUSINSKY A, KOZUBSKY W, SZULC-KUBERSKA J. Steroid treatment in the interruptions of clusters in cluster headache patients. Cephalalgia 1987; (Suppl 6):332-3.
214. ANTHONY M, DAHER BM. Mechanism of action of steroids in cluster headache. In: Rose FC, ed. New advances in headache research. London: Smith-Gordon, 1992:271-4.
215. EKBOM K, OLIVARIUS B. Chronic migrainous neuralgia: diagnostic and therapeutic aspects. Headache 1971;11:97-101.
216. EKBOM K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981;21:132-9.
217. BUSSONE G, LEONE M, PECCARISI C, MICIELI G, GRANELLA F et al. Double-blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990;30:411-7.
218. STEINER TJ, HERING R, COUTURIER EG, DAVIES PT, WHITMARSH TE. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997;17:673-5.
219. EKBOM K. Prophylactic treatment of cluster headache with a new serotonin antgonist, BC 105. Acta Neurol Scand 1969;45:601-10.
220. CURRAN DA, HINTERBERGER H, LANCE JW. Methysergide. Fali časopis 1967;1:74-122.
221. KRABBE A. Limited efficacy of methysergide in cluster headache: a clinical experience. Cephalalgia 1989;9:404-5.
222. HERING R, KURITZKY A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989;9:195-8.
223. WHEELER SD, CARRAZANA EJ. Topiramate-treated cluster headache. Neurology 1999;53:234-6.
224. WALDENLIND E, EKBOM K, WETTERBERG L et al. Lowered circannual urinary cluster headache. Cephalalgia 1994;14:199-204.
225. LEONE M, D'AMICO D, MOSCHIANO F, FRASCHINI F, BUSSONE G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996;16:494-6.
226. MARKS DR, RAPOPORT A, PADLA D et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993;13:114-6.
227. MATHER PJ, SILBERSTEIN SD, SCHULMAN EA, HOPKINS MM. The treatment of cluster headache with repetitive intraveneous dihydroergotamine. Headache 1991;31:525-32.
228. DODICK DW, ROZEN TD, GOADSBY PJ, SILBERSTEIN SD. Cluster headache. Fali časopis 2000;20:787-803.
229. ONOFRIO BM, CAMPBELL JK. Surgical treatment of chronic cluster headache. Mayo Clin Proc 1986;61:537-44.
230. MATHEW NT, HURT W. Percutaneous radiofrequency trigeminal gangliorhizolysis in intractable cluster headache. Headache 1988;28:328-31.
231. TAHA JM, TEW JM. Long-term results of radiofrequency rhizotomy in the treatment of cluster headache. Headache 1995;35:193-6.
232. PEPER DR, DICKERSON J, HASSENBUSCH SJ. Percutaneous retrogasserian glycerol rhizolysis for treatment of chronic intractable cluster headaches: long-term results. Neurosurgery 2000;46:363-8.
233. FORD RG, FORD KT, SWAID S, YOUNG P, JENELLE R. Gamma knife treatment of refractory cluster headache. Headache 1998;38:3-9.
234. ANTONACI F, SJAASTAD O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989;29:648-56.
235. EVERS S, GOADSBY PJ. Hypnic headache. Clinical features, pathophysiology and treatment. Neurology 2003;60:905-9.